Funding the Raise: SBA & Start-Up Loans

A collagen peptide brand is a consumer-packaged-goods and manufacturing play, not a clinic, and lenders read it that way. If you contract-manufacture and hold finished inventory, your business falls under manufacturing NAICS codes such as 311999 (other food manufacturing) or 325411 (medicinal and botanical manufacturing), and that classification matters when you apply for capital.

Manufacturing applicants clear the bar more often than service businesses: SBA 7(a) approval rates for manufacturers sit in roughly the 65–75% range, helped by equipment that can serve as collateral and historically lower default rates than services-led sectors (Crestmont Capital, 2026). A standard 7(a) loan runs up to $5M with terms up to 25 years, and the SBA has raised the cumulative 7(a) and 504 limit to $10M for borrowers who need to grow (U.S. Small Business Administration, 2026).

There is a NAICS-specific edge worth putting in your plan. The SBA's Manufacturing Access to Revolving Capital (MARC) facility is open only to NAICS 31–33 manufacturers and provides up to $5M in revolving working capital underwritten around how manufacturers actually consume cash. On top of that, manufacturing fee waivers (0% upfront on loans of $950K or less) run through 30 September 2026 (U.S. Small Business Administration). A collagen brand that orders inventory in 200–500kg batches lives and dies on working capital, so the revolving structure is often a better fit than a one-shot term loan.

In the UK, the government-backed Start Up Loan scheme provides up to £25,000 per founder at 6% fixed interest with free mentoring, and a co-founder team can stack individual loans. The figure rarely covers a full launch alone, so most UK collagen founders pair it with personal equity or an angel cheque. Whichever route you take, the lender wants the same thing: a financial model that shows when cash turns positive and how inventory is funded between production runs.

Equity routes exist too, but fit a particular ambition. A bootstrapped DTC brand can often reach profitability without outside equity if it stays disciplined on acquisition spend, and many of the most profitable collagen brands did exactly that. Angel or pre-seed money makes sense when you intend to spend ahead of revenue to capture shelf space quickly, or when you plan to move into retail where slotting and wholesale margin demand a bigger balance sheet. In the UK, founders sometimes structure an early raise to be SEIS or EIS eligible, which gives individual investors generous tax relief and makes a small cheque easier to close. Whichever instrument you choose, the document a funder reads first is the plan, and the section they scrutinise hardest is the cash-flow forecast around your inventory cycle.

One framing point is worth stating plainly because founders ask it constantly: a collagen brand is not a fast-cash business, it is a retention business. The first order rarely pays back the cost of acquiring the customer once you account for paid media; the profit is in the second, third and fourth tubs. That single fact should steer the whole financial model. It pushes you toward subscription, toward a primary segment that buys daily and habitually, and toward a funding ask large enough to survive the months between launch and the point where repeat revenue compounds. A plan that promises profit on first order is the plan a sophisticated lender stops reading.

The Collagen Peptide Market in 2026

Collagen peptides are hydrolysed collagen broken into short amino-acid chains, sold as powders, capsules, ready-to-drink shots and as a functional-food ingredient. The category sits at the intersection of nutraceuticals, beauty-from-within and sports nutrition, and demand has been driven by health-and-wellness spending plus the rise of marine and poultry-based sources prized for bioavailability.

Market sizing varies widely by analyst because each firm draws the category boundary differently. The collagen peptides segment was valued at over $3.34 billion in 2025 and is forecast to reach $7.44 billion by 2033 at a 10.5% CAGR on one estimate (Global Growth Insights, 2025). More conservative reads put the segment at $1.84 billion in 2025 growing to $2.96 billion by 2031 at an 8.43% CAGR (Mordor Intelligence, 2025). The honest move in your plan is to cite a range and footnote your chosen figure, not to pick the biggest number and hope nobody checks.

Where the demand actually sits

Three application buckets dominate spending. Nutritional supplements (powders, capsules, gummies) remain the largest and are where most new DTC brands enter. Cosmetics and beauty-from-within drinks are the fastest to command a premium price but carry the tightest claim rules. Food and beverage fortification, including protein bars and creamers, is a quieter B2B route where a brand sells the peptide as an ingredient rather than a finished consumer product.

Source choice shapes both cost and positioning. Bovine peptides (Type I and III, from cow hide) are the cheapest input and anchor the budget and mid tiers. Marine peptides (from fish skin and scales) are smaller, often marketed as more bioavailable, and carry a higher cost, which is exactly why brands lean on them to justify a premium price. Porcine and emerging sources such as egg-membrane collagen serve narrower niches. Your plan should state which source you use and why, because it determines your landed cost and your shelf message in one decision.

Who you are actually competing with

The shelf is crowded, and naming the real competition in your plan is what separates a credible analysis from a hopeful one. On the consumer side, Vital Proteins (founded 2013, grass-fed bovine, now owned by Nestlé) is the household name and effectively sets the reference price. Ancient Nutrition differentiates on a multi-collagen blend drawing from bovine, chicken, fish and eggshell membrane to cover collagen Types I, II, III, V and X. NeoCell has more than two decades in the category, while Sports Research, Further Food and Garden of Life compete on grass-fed sourcing, clean-label positioning and added biotin or vitamin C.

Behind every one of those labels sits a much shorter list of B2B ingredient houses. Gelita AG, Rousselot (active in over 60 countries) and Nitta Gelatin supply the actual peptide to most finished brands. That matters for a new entrant in two ways: first, your "secret" raw material is rarely unique, so differentiation has to come from format, audience or brand rather than the molecule; second, you can often buy a scientifically-documented peptide from the same source the incumbents use, which is a stronger story for a lender than an unverifiable proprietary claim.

A realistic competitor section maps three layers. Direct DTC brands compete on brand and retention. Amazon and retailer private label competes on price and discovery, and will always undercut you on a commodity bovine powder. Adjacent formats such as collagen gummies, creamers and ready-to-drink shots compete for the same wallet from a different shelf. The defensible position for a new brand is almost never "cheaper bovine powder"; it is a tighter audience, a differentiated format, or a marine and clinically-referenced premium tier the discounters cannot easily copy.

Who buys, and why it matters to the model

The core collagen buyer skews female, aged roughly 30 to 55, and is motivated by beauty-from-within, joint comfort or general wellness rather than a single acute problem. That buyer is high-intent and, crucially, habitual: collagen is consumed daily, which is what makes subscription work and what makes lifetime value the number that decides the business. A growing secondary segment is the active and sports-nutrition buyer who treats collagen as a recovery protein, and a third is the older-adult joint-health segment where clinical framing carries more weight.

Each segment changes the plan. The beauty buyer responds to brand, format and social proof and tolerates a premium price, which suits a marine or mid-to-premium positioning. The sports buyer is price-aware and bundle-driven, which points toward larger tubs and stacks. The joint-health buyer values evidence and consistency, which favours a clinically-referenced peptide and a steady reorder cadence. Your plan should pick a primary segment and write the acquisition channel, price tier and packaging to fit it, rather than trying to speak to all three at once.

What It Costs to Launch

A private-label launch is what keeps the entry cost low. Rather than building a facility, you brief a contract manufacturer that already holds the FDA-registered, GMP-certified plant, and you pay for a production run plus your own branding. A lean first launch typically lands between $18,000 and $50,000 (about £14,000 to £40,000); a fuller launch with paid acquisition, several SKUs and inventory cover reaches $150,000–$220,000 (£120,000–£175,000).

The cash trap is the minimum order quantity. Powder MOQs commonly run 200kg to 500kg per formula, set by the complexity of the formulation and ingredient procurement, which means your first cheque buys far more product than your first month of sales will move (Print Bind Ship private-label guide). Plan working capital around that gap, not around a single tub.

Line-item breakdown

• First private-label run (200–500kg MOQ + fill): $8,000–$45,000 (£6K–£36K)
• Formulation, R&D & stability testing: $3,000–$15,000 (£2.5K–£12K)
• Third-party COA, heavy-metal & microbial testing: $2,000–$8,000 (£1.6K–£6.5K)
• Branding, packaging & compliant labels: $2,000–$12,000 (£1.6K–£9.5K)
• Ecommerce build, photography & launch ads: $3,000–$140,000 (£2.5K–£110K)
• Working capital (next production run): hold cash for the second MOQ before the first sells through

Note what is missing compared with a clinic or a food-service concept: there is no premises fit-out, no kitchen and no front-of-house payroll in a private-label model. That is precisely why the floor is low and why a strong plan instead concentrates on inventory funding and customer-acquisition cost.

Choosing a contract manufacturer

Your operations section lives or dies on the manufacturer you name. Look for a partner that is FDA-registered, operates under 21 CFR Part 111 cGMP, and can document the source and purity of its collagen with third-party testing certificates. Certifications worth listing in the plan include GMP, ISO 9001, and, depending on your positioning, kosher, halal, paleo or keto marks that some buyers screen for. The category has a deep bench of private-label and contract houses, and your plan should show you have shortlisted and priced more than one rather than depending on a single quote.

Lead times and minimums shape your cash plan more than headline price. Formulating and producing a private-label supplement typically takes around four to six weeks once a formula is locked, and powder minimums commonly fall in the 200kg to 500kg band. Build those two numbers into a working-capital schedule: you place a second order weeks before the first sells through, so the model has to fund overlapping inventory, not a single run. This is the operational detail that reassures a lender you understand how the cash actually moves.

Two structural choices belong in this section as well. First, decide whether you stock and ship yourself, use third-party fulfilment, or run a hybrid; fulfilment cost per order materially changes the unit economics on a heavy powder tub. Second, decide your launch format. Powder is cheapest to produce and carries the best margin, capsules suit a convenience buyer at a lower serving size, and ready-to-drink or gummy formats command a premium but raise per-unit cost and complexity. A focused plan launches one format well rather than three at once.

Unit Economics & Margins

The market splits cleanly into three price bands per serving: a budget tier at roughly $0.80–$1.50, a mid-range tier at $1.50–$3.00 built on better ingredients for online sale, and a premium tier at $3.00–$6.00 reserved for marine collagen and clinically-referenced formulas. Most analysts and operators agree a private-label DTC brand runs a 55–75% gross margin, because the powder lands cheaply per serving while the retail price carries a wellness premium.

Where most guides stop at "high margin", the number that actually decides the business is contribution after acquisition. A collagen tub is bought repeatedly, so the model only works if customer lifetime value covers the cost of winning that customer plus the cost of goods on every reorder. Build the plan around repeat rate and average order value, not the headline gross margin.

A worked example

Take a bovine-peptide brand that lands finished powder at $0.55 per serving and sells a 30-serving tub at $34.99 ($1.17 per serving). Cost of goods on that tub is about $16.50, leaving roughly $18 gross per unit before shipping and payment fees. Move 1,500 tubs a month at a $26 blended net price (allowing for promotions and subscription discounts) and you reach about $468,000 in annual revenue. After cost of goods, fulfilment, payment fees and paid acquisition, a brand with healthy repeat behaviour lands in the 18–30% net margin band; one that has to buy every order through ads can fall to single digits.

Subscription is the lever that separates the two outcomes. A "subscribe and save" plan at 15% off lifts repeat purchase, smooths inventory planning against your MOQ, and is the single most important assumption to defend in front of a lender or investor. Bundles (a second SKU such as a marine "beauty" line or a collagen creamer) raise average order value without raising acquisition cost.

Channels and the cost of a customer

Most new collagen brands start direct-to-consumer because it keeps the full margin and gives clean data on repeat behaviour. The realistic acquisition mix is paid social (Meta and TikTok) for discovery, influencer and affiliate partnerships for trust in a category built on before-and-after storytelling, and email or SMS to drive the all-important second purchase. The danger is obvious: in a crowded category, paid acquisition cost rises over time, so a plan that assumes a flat customer-acquisition cost across three years is not credible. Model it climbing and let retention carry the economics.

Marketplace and retail are the other two routes, and each has a trade-off. Selling on Amazon buys discovery but exposes you to direct private-label price competition and thinner margin. Moving into bricks-and-mortar retail or pharmacy lifts volume but introduces wholesale margin and slotting costs that can halve your contribution per unit. A sensible plan sequences these: prove the product and retention DTC, then expand into marketplace and retail once the brand and repeat rate justify the lower per-unit margin.

Geography matters too. North America is the largest and most mature collagen market and the most competitive on acquisition cost, which is one reason many founders test a sharply-defined niche there rather than a broad launch. Europe and the UK grow steadily but are tighter on claims, as the licensing section sets out, so the marketing message has to be built compliantly from day one. Asia-Pacific is frequently cited as the fastest-growing region and is where premium marine and beauty-from-within positioning resonates most. If your plan targets more than one region, say which is primary and why, because acquisition strategy and claim rules differ enough that one playbook will not travel.

Three Ways to Build the Business

"Collagen peptide business" describes at least three different companies with different capital needs, margins and risks. Your plan should name which one you are, because investors price each model differently.

Most first-time founders start as a private-label DTC brand because it reaches the shelf fastest and uses a proven stock formula, which reduces both compliance testing and manufacturing risk. The ingredient route makes sense if you have a B2B relationship to anchor demand, and own-manufacturing is usually a later move once volume justifies the capex. Whichever you choose, the financial model and the funding ask change shape, so commit to one before you write the numbers.

Rules, Claims & Compliance

Collagen sits in food and supplement law, not drug law, but the claim rules are where founders get tripped up. The compliance section of your plan should read as confidently as your financials, because a single non-compliant claim can pull a product from a marketplace.

United States

The FDA does not pre-approve dietary supplements. Standard hydrolysed bovine and marine peptides were in the food supply before 15 October 1994, so they typically do not trigger a New Dietary Ingredient notification. A newer or genuinely novel source can, in which case you must file an NDI notification at least 75 days before introducing the product into interstate commerce (FDA, NDI Notification Process).

• Contract manufacturer must operate under cGMP, 21 CFR Part 111, including identity testing of every lot (a Certificate of Analysis alone is not enough)
• Supplement Facts panel and structure-function claims that comply with FDA labelling rules
• FDA facility registration for the manufacturing plant
• Heavy-metal and microbial testing documented for each production run

United Kingdom

Great Britain regulates collagen as a food supplement under FSA oversight, with labelling set by Directive 2002/46/EC carried into UK law. The decisive point for marketing: EFSA and the UK Nutrition and Health Claims Committee (NHCC) have authorised no direct collagen beauty claim, so "reduces wrinkles" or "supports skin" wording is not permitted on a UK or EU food supplement (UK Food Supplement Regulations guide, 2025).

• No pre-market licence to sell, but only claims on the official register may be used
• Compliant labelling, allergen declaration and a responsible business address
• Marketing built on compliant structure-function and lifestyle positioning, not unauthorised health claims

EU & other jurisdictions

• EU Novel Food (Reg. (EU) 2015/2283): standard bovine and marine peptides are generally not novel, but newer sources such as egg-membrane collagen peptides require EFSA novel-food authorisation before sale
• Canada (NNHPD): collagen is a Natural Health Product requiring a product licence and an eight-digit NPN printed on the pack

Mistakes That Sink the Raise

Across collagen plans that fail to fund, the same five errors recur. Each one is avoidable in the writing.

• Filing it as a "healthcare" or "wellness clinic" business. Collagen is consumer-packaged goods. Borrowing clinic financials (rooms, practitioners, insurance) makes the model unreadable to a CPG lender and inflates the cost base.
• Writing claims EFSA never approved. Anti-ageing and skin-benefit language is the fastest way to get pulled from Amazon UK and the EU. Position on lifestyle and compliant structure-function wording instead.
• Assuming all collagen is grandfathered. Most is, but skip the 75-day NDI question on a novel source and you can be selling illegally on day one.
• Underestimating the MOQ. A 200–500kg minimum order ties up cash in stock that may take months to move. Model the second run before the first sells through.
• Competing in the budget tier. Vital Proteins, Amazon private label and a wall of cheap bovine powder already own the bottom shelf. New brands win in the mid and premium tiers with a differentiated source, format or audience.

For deeper market sizing you can also cross-reference our market research and content service and the broader free business plan template library, then adapt a neighbouring consumer-goods plan such as our dietary supplements business plan template if you are bundling formats.

Sample Plan Preview

Here's an extract from a collagen peptide business plan written by our team, so you can see the level of specificity a funder expects:

What's in the Template

Every Avvale business plan template includes these sections, pre-structured for a collagen peptide brand:

• Executive Summary — Your brand, source choice and funding ask in 60 seconds
• Company Overview — Legal structure, NAICS classification, ownership and founding story
• Industry Analysis — Cited market range, application segments and source economics
• Customer Analysis — Target buyer, price tier and repeat-purchase behaviour
• Competitor Analysis — Where you sit against Vital Proteins, NeoCell and budget private label
• Marketing Plan — Acquisition channels, subscription offer and average-order-value levers
• Operations Plan — Contract manufacturer, MOQ, testing and inventory cadence
• Management Team — Founder bios, advisory and key hires

The optional Financial Forecast add-on (included in our $300/£250 and $1,000/£800 packages) provides a 5-year Excel model with income statement, cash flow, balance sheet, break-even analysis, and a working-capital schedule built around production-run timing — the part a collagen lender scrutinises most.

Frequently Asked Questions